Cyclic αvβ6-targeting peptide selected from biopanning with clinical potential for head and neck squamous cell carcinoma

Head and Neck

Volumn 32, Issue 2, 2010, Pages 160-172

  Hsiao, Jenn Ren ^a   Chang, Yao ^b   Chen, Yuh Ling ^a   Hsieh, Su Huei ^a   Hsu, Keng Fu ^a   Wang, Chun Fu ^c   Tsai, Sen Tien ^a   Jin, Ying Tai ^d  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^d Department of Pathology   (Taiwan)

Author keywords

Head and neck squamous cell carcinoma; Integrin v 6; Oral squamous cell carcinoma; Peptide; Phage display

Indexed keywords

ALPHAVBETA6 INTEGRIN; CD51 ANTIGEN; CYCLOPEPTIDE; PEPTIDE 29; RECEPTOR PROTEIN; UNCLASSIFIED DRUG; INTEGRIN; PEPTIDE; PEPTIDE LIBRARY; TUMOR ANTIGEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING ASSAY; BIOPANNING; CANCER CELL CULTURE; CARCINOMA CELL; CELL PROLIFERATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG POTENCY; DRUG SPECIFICITY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHARYNX CARCINOMA; IMMUNOFLUORESCENCE; INHIBITION KINETICS; LARYNX CARCINOMA; MOUTH CARCINOMA; NASOPHARYNX CARCINOMA; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RECEPTOR BINDING; SQUAMOUS CELL CARCINOMA; TARGET CELL; TISSUE SECTION; CELL ADHESION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; METABOLISM; MOUTH TUMOR; TUMOR CELL LINE;

ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRINS; MICROSCOPY, CONFOCAL; MOUTH NEOPLASMS; PEPTIDE LIBRARY; PEPTIDES;

EID: 74749088094     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21166     Document Type: Article

References (42)

1. Mignogna MD, Fedele S, Lo Russo L. The World Cancer Report and the burden of oral cancer. Eur J Cancer Prev 2004;13:139-142.
2. Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer J Clin 2002;52:195-215.
3. Samoylova TI, Morrison NE, Globa LP, Cox NR. Peptide phage display: opportunities for development of personalized anti-cancer strategies. Anticancer Agents Med Chem 2006;6:9-17.
4. Mori T. Cancer-specific ligands identified from screening of peptide-display libraries. Curr Pharm Des 2004;10: 2335-2343.
5. Landon LA, Zou J, Deutscher SL. Is phage display technology on target for developing peptide-based cancer drugs? Curr Drug Discov Technol 2004;1:113-132.
6. Humphrey JM, Chamberlin AR. Chemical synthesis of natural product peptides: coupling methods for the incorporation of noncoded amino acids into peptides. Chem Rev 1997;97:2243-2266.
7. Rikimaru K, Toda H, Tachikawa N, Kamata N, Enomoto S. Growth of the malignant and nonmalignant human squamous cells in a protein-free defined medium. In Vitro Cell Dev Biol 1990;26:849-856.
8. Wilkins JA, Li A, Ni H, Stupack DG, Shen C. Control of β1 integrin function. Localization of stimulatory epitopes. J Biol Chem 1996;271:3046-3051.
9. Carter WG, Wayner EA, Bouchard TS, Kaur P. The role of integrins a2b1 and a3b1 in cell-cell and cell-substrate adhesion of human epidermal cells. J Cell Biol 1990;110:1387-1404.
10. Weinacker A, Chen A, Agrez M, et al. Role of the integrin αvβ6 in cell attachment to fibronectin. Heterologous expression of intact and secreted forms of the receptor. J Biol Chem 1994;269:6940-6948.
11. Elayadi AN, Samli KN, Prudkin L, et al. A peptide selected by biopanning identifies the integrin αvβ6 as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res 2007;67:5889-5895.
12. Chen P, Melchior C, Brons NH, Schlegel N, Caen J, Kieffer N. Probing conformational changes in the I-like domain and the cysteine-rich repeat of human β3 integrins following disulfide bond disruption by cysteine mutations: identification of cysteine 598 involved in αIIbβ3 activation. J Biol Chem 2001;276: 38628-38635.
13. Cambier S, Gline S, Mu D, et al. Integrin αvβ8-mediated activation of transforming growth factor-beta by perivascular astrocytes: an angiogenic control switch. Am J Pathol 2005;166:1883-1894.
14. De Nichilo MO, Yamada KM. Integrin αvβ5-dependent serine phosphorylation of paxillin in cultured human macrophages adherent to vitronectin. J Biol Chem 1996; 271:11016-11022.
15. Mateu MG, Valero ML, Andreu D, Domingo E. Systematic replacement of amino acid residues within an Arg-Gly-Asp-containing loop of foot-and-mouth disease virus and effect on cell recognition. J Biol Chem 1996;271: 12814-12819.
16. Jackson T, Sheppard D, Denyer M, Blakemore W, King AM. The epithelial integrin αvβ6 is a receptor for foot-and-mouth disease virus. J Virol 2000;74:4949-4956.
17. Duque H, Baxt B. Foot-and-mouth disease virus receptors: comparison of bovine αv integrin utilization by type A and O viruses. J Virol 2003;77:2500-2511.
18. O'Donnell V, LaRocco M, Duque H, Baxt B. Analysis of foot-and-mouth disease virus internalization events in cultured cells. J Virol 2005;79:8506-8518.
19. Jackson T, Mould AP, Sheppard D, King AM. Integrin αvβ1 is a receptor for foot-and-mouth disease virus. J Virol 2002;76:935-941.
20. Jackson T, Clark S, Berryman S, et al. Integrin αvβ8 functions as a receptor for foot-and-mouth disease virus: role of the beta-chain cytodomain in integrin-mediated infection. J Virol 2004;78:4533-4540.
21. Nishimura SL, Sheppard D, Pytela R. Integrin αvβ8. Interaction with vitronectin and functional divergence of the beta 8 cytoplasmic domain. J Biol Chem 1994;269: 28708-28715.
22. 2-terminal regulatory site on the β1 integrin chain. J Biol Chem 1998; 273:7981-7987.
23. Xue H, Atakilit A, Zhu W, Li X, Ramos DM, Pytela R. Role of the αvβ6 integrin in human oral squamous cell carcinoma growth in vivo and in vitro. Biochem Biophys Res Commun 2001;288:610-618.
24. Puri SK, Fan CY, Hanna E. Significance of extracapsular lymph node metastases in patients with head and neck squamous cell carcinoma. Curr Opin Otolaryngol Head Neck Surg 2003;11:119-123.
25. Thomas GJ, Nystrom ML, Marshall JF. αvβ6 integrin in wound healing and cancer of the oral cavity. J Oral Pathol Med 2006;35:1-10.
26. Burman A, Clark S, Abrescia NG, Fry EE, Stuart DI, Jackson T. Specificity of the VP1 GH loop of foot-and-mouth disease virus for av integrins. J Virol 2006; 80:9798-9810.
27. Berryman S, Clark S, Monaghan P, Jackson T. Early events in integrin αvβ6-mediated cell entry of foot-and-mouth disease virus. J Virol 2005;79:8519-8534.
28. Kraft S, Diefenbach B, Mehta R, Jonczyk A, Luckenbach GA, Goodman SL. Definition of an unexpected ligand recognition motif for αvβ6 integrin. J Biol Chem 1999; 274:1979-1985.
29. Healy JM, Murayama O, Maeda T, Yoshino K, Sekiguchi K, Kikuchi M. Peptide ligands for integrin αvβ3 selected from random phage display libraries. Biochemistry 1995;34:3948-3955.
30. Koivunen E, Wang B, Ruoslahti E. Isolation of a highly specific ligand for the α5β1 integrin from a phage display library. J Cell Biol 1994;124:373-380.
31. Gu J, Taniguchi N. Regulation of integrin functions by N-glycans. Glycoconj J 2004;21:9-15.
32. Oyama T, Sykes KF, Samli KN, Minna JD, Johnston SA, Brown KC. Isolation of lung tumor specific peptides from a random peptide library: generation of diagnostic and cell-targeting reagents. Cancer Lett 2003;202:219-230.
33. DiCara D, Rapisarda C, Sutcliffe JL, et al. Structure-function analysis of Arg-Gly-Asp helix motifs in αvβ6 integrin ligands. J Biol Chem 2007;282:9657-9665.
34. Ramsay AG, Keppler MD, Jazayeri M, et al. HS1-associated protein X-1 regulates carcinoma cell migration and invasion via clathrin-mediated endocytosis of integrin αvβ6. Cancer Res 2007;67:5275-5284.
35. van der Pluijm G, Vloedgraven HJ, Ivanov B, et al. Bone sialoprotein peptides are potent inhibitors of breast cancer cell adhesion to bone. Cancer Res 1996;56:1948-1955.
36. Breuss JM, Gallo J, DeLisser HM, et al. Expression of the β6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J Cell Sci 1995;108:2241-2251.
37. Jones J, Watt FM, Speight PM. Changes in the expression of av integrins in oral squamous cell carcinomas. J Oral Pathol Med 1997;26:63-68.
38. Regezi JA, Ramos DM, Pytela R, Dekker NP, Jordan RC. Tenascin and β6 integrin are overexpressed in floor of mouth in situ carcinomas and invasive squamous cell carcinomas. Oral Oncol 2002;38:332-336.
39. Impola U, Uitto VJ, Hietanen J, et al. Differential expression of matrilysin-1 (MMP-7), 92 kD gelatinase (MMP-9), and metalloelastase (MMP-12) in oral verrucous and squamous cell cancer. J Pathol 2004;202:14-22.
40. Hamidi S, Salo T, Kainulainen T, Epstein J, Lerner K, Larjava H. Expression of αvβ6 integrin in oral leukoplakia. Br J Cancer 2000;82:1433-1440.
41. Bates RC, Bellovin DI, Brown C, et al. Transcriptional activation of integrin β6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest 2005;115:339-347.
42. Hazelbag S, Kenter GG, Gorter A, et al. Overexpression of the αvβ6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. J Pathol 2007;212:316-324.